For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

Moderna has been saying for years that it would diversify its portfolio beyond infectious diseases. Investors were waiting for late-stage proof. On Wednesday, they got it. Moderna's shares soared to multiyear highs after disclosing